For patients suffering from fibrodysplasia ossificans progressiva, or F.O.P., a rare genetic disorder that causes uncontrolled bone growth in muscles and connective tissue, there is finally tangible hope. The condition, which slowly turns soft tissues into bone, was identified in many cases only after years of observation, such as when Jordyn Bugarin's grandmother recognized the symptoms on a 2006 television documentary.
Although the mutated gene responsible for F.O.P. was discovered two decades ago, no approved treatments existed until recently. The landscape has now shifted with the authorization of three distinct therapies. In August, the Food and Drug Administration approved garetosmab, marketed as Pasatru by Regeneron. This monoclonal antibody has demonstrated significant efficacy, reducing new abnormal bone formation by 90 percent in patients, marking it as the most effective treatment available to date.
Two other medications have also received approval: zilurgisertib (Atebrioz), which inhibits the ALK2 protein that directs bone growth, and palovarotene (Sohonos), designed to override signals prompting excessive bone development. However, while these options represent a breakthrough, some patients face serious side effects, and their overall effectiveness has not always met researchers' initial expectations.
For young adults like Ms. Bugarin, now 22, the availability of these drugs is transformative. Describing the situation as feeling like a dream, she noted that witnessing such medical progress was something she never expected to see within her lifetime.
Sources: The New York Times Science.